Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

RVC gets funding to develop organ-on-a-chip facility
The facility will reduce the amount of animals needed for in-vitro testing.

It will be the first organ-on-a-chip facility created for veterinary species.

The Royal Veterinary College (RVC) researchers have been awarded a grant which will allow them to develop the first ever organ-on-a-chip facility for veterinary species, reducing the amount of animals needed for in-vitro testing.

Organs-on-chips (OoC) are systems that contain engineered or natural miniature tissues grown inside microfluidic chips.

They are developed to mimic species physiology better than traditional 2D cell culturing, controlling cell microenvironments and maintaining structures and functions of tissues and organs, such as the blood-brain barrier, lungs and heart, while being constantly supplied with necessary nutrients.

The technology will reflect animal tissue structures to predict responses to a wide range of stimuli, including vaccines, pathogens, environmental conditions and cell-to-cell interactions.

This will help bridge the gap between animal and human systems, allowing for drug and vaccine testing and studies into how cells interact with each other and pathogens without the use of live animal testing.

The RVC’s OoC project has been funded by UK Research and Innovation to assess the development of new vaccines and vaccine approaches by better understanding host-pathogen interactions

This will also develop regenerative medicine therapies such as stem cell therapy for tendon, heart and eye conditions, kidney failure and cancers in multi-cell systems.

The research will be led by RVC’s newly created Centre for Vaccinology and Regenerative Medicine.

Dirk Werling, professor of molecular immunology at the RVC, said: “The organ-on-a-chip is one of the top 10 emerging technologies and we are very proud to be able to establish this technology at the RVC, thus actively contributing to the development of new treatment strategies as well as further reducing the usage of animals for in-vivo testing and therefore contributing to the 3Rs – replacement, reduction and refinement.”

Image (C) RVC

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.